Suspected Complicated UTI
Urinary symptoms + signs of upper tract involvement or complicating factors
All Pathways
Infectious DiseaseManagement
Complicated UTI & Pyelonephritis Management (IDSA 2025)
Complicated UTI & Pyelonephritis Management (IDSA 2025): Suspected Complicated UTI → cUTI Definition (IDSA 2025) → Initial Workup → Sepsis Present? → Ur...
Pathway Overview
16 steps
Algorithm Steps
16 total
01Start 02Action cUTI Definition (IDSA 2025)
Infection beyond the bladder
- Pyelonephritis (flank pain, CVA tenderness, fever)
- UTI in men
- UTI with anatomic/functional abnormalities
- Catheter-associated UTI (CAUTI)
- UTI with sepsis
03Action Initial Workup
Urine culture and labs
- Urinalysis + Urine culture with susceptibilities
- Blood cultures if sepsis or immunocompromised
- BMP (renal function), CBC
- Review prior urine cultures for resistance patterns
- Imaging: CT or US if complicated (abscess, obstruction, stones)
04Decision Sepsis Present?
Assess severity of illness
- Sepsis: SIRS criteria + infection source
- Septic shock: Vasopressors required
- Urosepsis: 20-30% of sepsis cases
05Action Urosepsis Management
Aggressive treatment required
- IV antibiotics within 1 hour
- Piperacillin-tazobactam 4.5g IV q6h, OR
- Meropenem 1g IV q8h (if ESBL risk), OR
- Ceftriaxone 1-2g IV daily (if low resistance)
- ADD Vancomycin if gram-positive suspected
- Source control: Decompress obstruction urgently
06Decision Risk for Resistant Organisms?
ESBL, Pseudomonas, MDR
- Prior resistant isolate
- Recent antibiotic use (esp. FQ in past 12 months)
- Healthcare exposure, catheter
- Travel to high-resistance area
07Action ESBL/MDR Coverage
Carbapenem or alternative
- Ertapenem 1g IV daily (preferred for ESBL)
- Meropenem 1g IV q8h (if Pseudomonas risk)
- Alternatives if carbapenem-sparing needed:
- Aminoglycosides (if susceptible)
- Ceftazidime-avibactam, Ceftolozane-tazobactam
08Action CAUTI-Specific Management
If catheter-associated
- Remove or replace catheter (strongly recommended)
- Duration: 7 days (if symptoms resolve promptly)
- May extend to 10-14 days if slower response
- Do NOT treat asymptomatic bacteriuria in catheterized patients
09Action Duration of Therapy
Shorter courses now recommended
- Uncomplicated pyelonephritis: 5-7 days (FQ) or 7 days (other)
- Complicated UTI: 7-10 days
- CAUTI: 7 days if prompt response
- Prostatitis: 14-28 days (if prostate involved)
- Do NOT use longer courses routinely
10Decision Clinical Response by 48-72h?
Assess for improvement
11Outcome Improving
Continue course, step down
- IV to PO transition when appropriate
- Complete antibiotic course
- No routine test of cure culture needed
12Warning Treatment Failure
Persistent symptoms/fever
- Repeat imaging (CT): Rule out abscess, obstruction
- Repeat urine culture
- Consider resistant organism, wrong diagnosis
- Urology consultation if structural issue
- Broaden antibiotic coverage
13Action Standard Coverage Adequate
Continue empiric or narrow based on culture
- Narrow to susceptibility results
- Oral step-down when criteria met
- De-escalate from broad-spectrum when possible
- Path rejoins step 08Shared downstream outcome
14Decision Outpatient or Inpatient?
Based on ability to tolerate PO, severity
15Action Outpatient Treatment
Mild-moderate, can tolerate PO
- Fluoroquinolone x5-7 days (if susceptible, no recent FQ use):
- Ciprofloxacin 500mg PO BID or Levofloxacin 750mg daily
- OR TMP-SMX DS BID x7 days (if susceptible)
- OR Amoxicillin-clavulanate 875mg PO BID x7 days
- Consider one-time IV ceftriaxone 1g then oral therapy
- Path rejoins step 06Shared downstream outcome
16Action Inpatient IV Treatment
Cannot tolerate PO, moderate-severe
- Ceftriaxone 1-2g IV daily, OR
- Ciprofloxacin 400mg IV q12h, OR
- Ertapenem 1g IV daily (if ESBL risk)
- Step down to oral when afebrile x24-48h, tolerating PO
- Path rejoins step 06Shared downstream outcome
Guideline Source
IDSA 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Local resistance patterns should guide empiric therapy
- Prior urine culture results important for empiric selection
- Catheter-associated UTI has specific considerations
- Prostatitis requires longer treatment duration
- Pregnancy requires specific antibiotic choices
Applicable Regions
USEU
Version 1Next review: 2027-01-11
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Complicated UTI & Pyelonephritis Management (IDSA 2025)?
The Complicated UTI & Pyelonephritis Management (IDSA 2025) is a management clinical algorithm for Infectious Disease. It provides a structured decision tree to guide clinical decision-making, based on IDSA 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections.
What guideline is the Complicated UTI & Pyelonephritis Management (IDSA 2025) based on?
This algorithm is based on IDSA 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections (DOI: 10.1093/cid/ciaf460).
What are the limitations of the Complicated UTI & Pyelonephritis Management (IDSA 2025)?
Known limitations include: Local resistance patterns should guide empiric therapy; Prior urine culture results important for empiric selection; Catheter-associated UTI has specific considerations; Prostatitis requires longer treatment duration; Pregnancy requires specific antibiotic choices. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Complicated UTI & Pyelonephritis Management (IDSA 2025) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free